Tonira Pharma Ltd Stock Analysis

BSE: 530155 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Tonira Pharma

M-Cap below 100cr DeciZen not available

Tonira Pharma Price Chart

P/E Ratio ( SA) :
Market Cap :
15.7 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Tonira Pharma Ltd. a good quality company?

Data is not available for this company.

2. Is Tonira Pharma Ltd. undervalued or overvalued?

No data found

3. Is Tonira Pharma Ltd. a good buy now?

No data found

10 Year X-Ray of Tonira Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 13.7%17.5%2.5%6.7%7.5%7.5%-4.7%10.8%6.2%-1.8%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 19.42426.222.529.436.832.641.336.930.233
YoY Gr. Rt. %-23.3%9.1%-13.8%30.3%25.2%-11.5%26.8%-10.7%-18.1%-
YoY Gr. Rt. %-44.5%-96.5%1425%25.1%-6.1%-300.5%NA-66.9%-565.9%-
BVPS (₹) 15.416.517.5212324.717.516.418.115.412.5
Adj Net Profit
Cash Flow from Ops.
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5%0.6%-2.5%-18.1%
Adj EPS -205.4%-210.8%NA-565.9%
BVPS 0-7.7-4-14.5
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 16.2210.79.410.38.9-2014.44.8-22.8-30.2
Op. Profit Mgn %
Net Profit Mgn % 9.711.
Debt to Equity
Working Cap Days 2191821571861851892402112483140
Cash Conv. Cycle 122806493971001281001311870

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Tonira Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) -4.2 -2.6
TTM Sales (₹ Cr.) 33.5 30.2
BVPS (₹.) 12.5 15.3
Reserves (₹ Cr.) 2 4
P/BV 1.58 1.29
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 19.00 / 19.90
All Time Low / High (₹) 0.80 / 50.30
Market Cap (₹ Cr.) 15.7
Equity (₹ Cr.) 7.9
Face Value (₹) 10
Industry PE 36.3

Management X-Ray of Tonira Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Tonira Pharma

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Tonira Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Tonira Pharma on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Tonira Pharma stood at ₹ 15.69.
The latest PE ratio of Tonira Pharma as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of Tonira Pharma as of 01-Jan-1970 05:30 is 1.58
The 52-week high of Tonira Pharma is ₹ 19.90 and the 52-week low is ₹ 19.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Tonira Pharma is ₹ 33.49 ( Cr.) .

About Tonira Pharma Ltd

Tonira Pharma incorporated, in 1992, is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates.

The company's manufacturing locations at Nandesari and Ankleshwar are inspected and approved by PMDA Japan. With the USFDA approval of the Nandesari plant and PMDA Japan approvals of both the plants, the company will now have access to regulated markets for its APIs.

Tonira operates a state-of-the-art R&D Center at Nandesari, Vadodara District in Gujarat. The centre is continuously developing newer value-added APIs through innovative and cost-effective processes.

Tonira undertakes contract synthesis both on exclusive and non-exclusive basis.  The company has the capability to provide contract research and manufacturing services to its customers.


APIs- Under this, the company manufactures Atenolo, Aceclofenac, Benzbromarone, Benzarone, Desloratadine, Ebastine, Famotidine, Glimepiride, Loratadine, Meloxicam, Mosapride Citrate, Nifedipine, Ofloxacin, Quetiapine Fumarate, Sodium Alendronate, Tramadol HCI, Tamsulosin HCI and Zolpidem Tartrate.


  • Tonira Pharma has received WHO-GMP approval for its manufacturing facility.
  • The company is recipient of export award for two successive years from DGFT.
  • Its R&D centre is recognized by Department of Science & Technology, Government of India.
  • The company has been recognised as an Export House by Government of India.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now